We found that the gene mutation profiles of short- and long-lived DNMT3A-mutated TCGA AML patients enabled to separate the 208 DNMT3A-mutant AML patients from the German-Austrian AML Study Group into a short- and long-lived subgroup that differed significantly in survival (Fig. 5A, log-rank test: P < 0.003). This evidence concerns the gene DNMT3A and acute myeloid leukemia.